WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use

Erin Sparrow; Ifedayo Adetifa; Nathorn Chaiyakunapruk; Thomas Cherian; Deshayne B Fell; Barney S Graham; Bruce Innis; David C Kaslow; Ruth A Karron; Harish Nair; Kathleen M Neuzil; Samir Saha; Peter G Smith; Padmini Srikantiah; Fred Were; Heather J Zar; Daniel Feikin

doi:10.1016/j.vaccine.2022.02.040

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use

Erin Sparrow, Ifedayo Adetifa, Nathorn Chaiyakunapruk, Thomas Cherian, Deshayne B Fell, Barney S Graham, Bruce Innis, David C Kaslow, Ruth A Karron, Harish Nair, Kathleen M Neuzil, Samir Saha, Peter G Smith, Padmini Srikantiah, Fred Were, Heather J Zar, Daniel Feikin

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.

Original language	English
Pages (from-to)	3506-3510
Journal	Vaccine
Volume	40
Issue number	26
Early online date	17 Feb 2022
DOIs	https://doi.org/10.1016/j.vaccine.2022.02.040
Publication status	Published - 9 Jun 2022

Keywords / Materials (for Non-textual outputs)

Antibodies, Monoclonal/therapeutic use
Antibodies, Viral
Child
Communicable Diseases
Humans
Immunization, Passive
Infant
Respiratory Syncytial Virus Infections/prevention & control
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus, Human
World Health Organization

Access to Document

10.1016/j.vaccine.2022.02.040Licence: Creative Commons: Attribution (CC-BY)

ErinSparrowAccepted author manuscript, 268 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Cite this

Sparrow, E., Adetifa, I., Chaiyakunapruk, N., Cherian, T., Fell, D. B., Graham, B. S., Innis, B., Kaslow, D. C., Karron, R. A., Nair, H., Neuzil, K. M., Saha, S., Smith, P. G., Srikantiah, P., Were, F., Zar, H. J., & Feikin, D. (2022). WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use. Vaccine, 40(26), 3506-3510. https://doi.org/10.1016/j.vaccine.2022.02.040

@article{4d241c6fa7674bc7a9d7f2b86e9b781b,

title = "WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use",

abstract = "World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.",

keywords = "Antibodies, Monoclonal/therapeutic use, Antibodies, Viral, Child, Communicable Diseases, Humans, Immunization, Passive, Infant, Respiratory Syncytial Virus Infections/prevention & control, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, World Health Organization",

author = "Erin Sparrow and Ifedayo Adetifa and Nathorn Chaiyakunapruk and Thomas Cherian and Fell, {Deshayne B} and Graham, {Barney S} and Bruce Innis and Kaslow, {David C} and Karron, {Ruth A} and Harish Nair and Neuzil, {Kathleen M} and Samir Saha and Smith, {Peter G} and Padmini Srikantiah and Fred Were and Zar, {Heather J} and Daniel Feikin",

note = "Funding Information: This work was supported by the Bill & Melinda Gates Foundation (Grant number: OPP1114766) to the World Health Organization. The funder had no role in the approval of this document. Publisher Copyright: {\textcopyright} 2022 World Health Organization. Published by Elsevier Ltd.",

year = "2022",

month = jun,

day = "9",

doi = "10.1016/j.vaccine.2022.02.040",

language = "English",

volume = "40",

pages = "3506--3510",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "26",

}

Sparrow, E, Adetifa, I, Chaiyakunapruk, N, Cherian, T, Fell, DB, Graham, BS, Innis, B, Kaslow, DC, Karron, RA, Nair, H, Neuzil, KM, Saha, S, Smith, PG, Srikantiah, P, Were, F, Zar, HJ & Feikin, D 2022, 'WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use', Vaccine, vol. 40, no. 26, pp. 3506-3510. https://doi.org/10.1016/j.vaccine.2022.02.040

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use. / Sparrow, Erin; Adetifa, Ifedayo; Chaiyakunapruk, Nathorn et al.
In: Vaccine, Vol. 40, No. 26, 09.06.2022, p. 3506-3510.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use

AU - Sparrow, Erin

AU - Adetifa, Ifedayo

AU - Chaiyakunapruk, Nathorn

AU - Cherian, Thomas

AU - Fell, Deshayne B

AU - Graham, Barney S

AU - Innis, Bruce

AU - Kaslow, David C

AU - Karron, Ruth A

AU - Nair, Harish

AU - Neuzil, Kathleen M

AU - Saha, Samir

AU - Smith, Peter G

AU - Srikantiah, Padmini

AU - Were, Fred

AU - Zar, Heather J

AU - Feikin, Daniel

N1 - Funding Information: This work was supported by the Bill & Melinda Gates Foundation (Grant number: OPP1114766) to the World Health Organization. The funder had no role in the approval of this document. Publisher Copyright: © 2022 World Health Organization. Published by Elsevier Ltd.

PY - 2022/6/9

Y1 - 2022/6/9

N2 - World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.

AB - World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.

KW - Antibodies, Monoclonal/therapeutic use

KW - Antibodies, Viral

KW - Child

KW - Communicable Diseases

KW - Humans

KW - Immunization, Passive

KW - Infant

KW - Respiratory Syncytial Virus Infections/prevention & control

KW - Respiratory Syncytial Virus Vaccines

KW - Respiratory Syncytial Virus, Human

KW - World Health Organization

U2 - 10.1016/j.vaccine.2022.02.040

DO - 10.1016/j.vaccine.2022.02.040

M3 - Article

C2 - 35184927

SN - 0264-410X

VL - 40

SP - 3506

EP - 3510

JO - Vaccine

JF - Vaccine

IS - 26

ER -

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this